Last reviewed · How we verify
Methylprednisolone Injectable Product
Methylprednisolone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Methylprednisolone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Acute inflammation and immune-mediated conditions, Multiple sclerosis exacerbations, Severe allergic reactions.
At a glance
| Generic name | Methylprednisolone Injectable Product |
|---|---|
| Also known as | Prednisone, solu madrol |
| Sponsor | Vanderbilt University Medical Center |
| Drug class | Glucocorticoid (corticosteroid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Neurology, Oncology (supportive care) |
| Phase | FDA-approved |
Mechanism of action
Methylprednisolone acts as a potent corticosteroid that crosses cell membranes and binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene expression. This results in decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppression of immune cell activation and proliferation. The injectable formulation allows for rapid systemic delivery and is used in acute inflammatory and immunological conditions.
Approved indications
- Acute inflammation and immune-mediated conditions
- Multiple sclerosis exacerbations
- Severe allergic reactions
- Autoimmune disorders
- Cerebral edema
- Spinal cord injury (acute)
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Mood changes (euphoria, anxiety)
- Immunosuppression / increased infection risk
- Osteoporosis (with chronic use)
- Gastrointestinal upset
Key clinical trials
- OMT for Adhesive Capsulitis (PHASE4)
- Arthrosemid vs. Steroid for the Management Knee Osteoarthritis (PHASE4)
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- Post-operative Methylprednisolone Taper Course for Orthopedic Surgery (PHASE4)
- Combination of Fluoroscopy and Ultrasonography Guidance in Sacroiliac Joint Injections. A Randomised Controlled Trial (NA)
- Daratumumab in STK11 Mutated NSCLC (PHASE2)
- Efficacy of Nerve Blocks for Episodic Migraine (PHASE2)
- Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: